GenSight scuttles its planned $65M IPO

GenSight Biologics has postponed its plans to go public after repeatedly downsizing its ambition, marking the latest setback for Wall Street-bound biotechs dealing with a sectorwide downturn. The Parisian company set out to raise $100 million with its first filing over the summer, gradually scaling back its planned offering before settling on an effort to price about 4.7 million shares at $13 to $15 each. That goal will now have to wait as the biotech put on hold its Nasdaq debut, which would have helped fund its work to develop a gene therapy for rare, vision-destroying diseases. More

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.